SCHEMBL2826499

SCHEMBL2826499

CCOC(=O)c1ncc(C(C)C)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
KDM4E B2RXH2 4/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
GSK3B P49841 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 4/20 0.40
MAPK1 P28482 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 2/20 0.39
GABRA1 P14867 4/20 0.38
GABRB2 P47870 4/20 0.38
GABRA2 P47869 3/20 0.38
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
MAPT P10636 2/20 0.38
GABRB1 P18505 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24112533 0.80 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL21187205 0.80 KMT2A (0.46) ALDH1A1SMN1; SMN2LMNAMAPK1L3MBTL1
SCHEMBL2823462 0.80 KDM4E (0.47) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL24898305 0.77 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL24215454 0.77 KDM4E (0.45) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL2823105 0.77 KDM4E (0.45) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL1079026 0.76 SMN1; SMN2 (0.52) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL30889539 0.75 HCAR3 (0.43) LMNA
SCHEMBL1079090 0.75 KDM4E (0.50) ALDH1A1KDM4EHPGDHTTRECQL
SCHEMBL2825211 0.75 HSP90AA1 (0.46) ALDH1A1KDM4EHPGDHTTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4268824-A1 IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT Manros Therapeutics (FR) 2023-11-01 EP disclosed
EP-4268824-A1 IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT Manros Therapeutics (FR) 2023-11-01 EP disclosed
EP-2226322-B1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO CO LTD (JP) 2015-01-21 EP disclosed
US-8927588-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-01-06 US disclosed
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
US-8536197-B2 Imidazole carbonyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-09-17 US disclosed
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-12-09 US disclosed
EP-2226322-A1 IMIDAZOLE CARBONYL COMPOUND Daiichi Sankyo Company, Limited (JP) 2010-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311966-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A ALDH1A1 3596/4885KDM4E 206/4885HPGD 1751/4885
US-20140073622-A1 IMIDAZOLE CARBONYL COMPOUND TOP1, TOP2B, TOP2A ALDH1A1 1220/4885KDM4E 211/4885HPGD 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.